Gene expression and chromatin accessibility during progressive EMT and MET linked to dynamic CTCF engagement

Kelsey S. Johnson¹, Shaimaa Hussein², Shuxuan Song¹, Priyanka Chakraborty³, Mohit Kumar Jolly³, Michael J. Toneff⁴, Yin C. Lin², Joseph H. Taube^{1,5,6#}

¹Department of Biology, Baylor University, Waco, TX, USA

²Baylor Institute for Immunology Research, Baylor Scott & White, Dallas, TX, USA

³Centre for BioSystems Science and Engineering, Indian Institute of Science, Bangalore 560012, India

⁴Department of Biology, Widener University, Chester, PA, USA

⁵Institute for Biomedical Studies, Baylor University, Waco, TX, USA

⁶Dan L. Duncan Cancer Center, Houston, TX, USA

[#]Corresponding author: Joseph_Taube@baylor.edu

Abstract

Background: Epithelial-mesenchymal transition (EMT) facilitates cellular movements critical for proper development; however, in a carcinoma, EMT promotes metastatic dissemination. Stable intermediate states (partial-EMT) are increasingly implicated in metastatic dissemination while reversal of EMT, termed mesenchymal-epithelial transition (MET), is increasingly implicated in metastatic colonization. To understand the partial and reversible nature of EMT, we characterized chromatin accessibility dynamics, transcriptome changes, protein expression patterns, as well as E-cadherin expression, localization, and gene-level dynamics in mammary epithelial cells undergoing stepwise reversible EMT.

Results: While shorter EMT induction induced internalization of E-cadherin protein, surface expression was recovered upon MET without loss of transcript or bulk protein. Conversely, a longer EMT induced stable repression of E-cadherin indicated by loss of chromatin accessibility and induced global expansion of accessible sites across the genome, facilitated by increased engagement of multiple transcription factor families, including AP-1 and SMAD. We observe enrichment for binding sites for the insulator proteins CTCF and BORIS was significantly diminished in both stemness-enriched partial-EMT and partial-MET states and determined that CTCF repression imparts alterations in some histone covalent modifications concomitant with those observed during TGF β -induced EMT.

Conclusions: These findings are indicative of a major role for chromatin looping and reorganization in plasticity, stemness, and partial EMT phenotypes.

Keywords

EMT, MET, partial EMT, ATAC-seq, chromatin accessibility, CTCF, E-cadherin

Background

Epithelial-mesenchymal transition (EMT) is a conserved cellular process that drives programs such as gastrulation and wound healing. During EMT, epithelial cells alter their gene expression and morphology, lose cell-cell contacts, and adopt a mesenchymal-like state (1). Because this process promotes invasion, intravasation, and resistance to anoikis in tumor cells, the EMT program is also implicated in metastatic dissemination (2-4). Recent work has contributed to a revised model of metastasis in which reversal of EMT, mesenchymal-epithelial transition (MET), is necessary for colonization of cells which arrive at the metastatic site by means of an EMT (5-8). Thus, understanding the factors that impact the reversibility of EMT is critical to developing better anti-metastasis treatments.

EMT propels cells through a progressive adoption of gene expression changes leading to phenotypic alterations. While a hallmark of EMT is the suppression of genes such as E-cadherin (*CDH1*) and epithelial cell adhesion molecule (*EPCAM*), there are also profound changes throughout the epigenome, transcriptome, spliceosome, and protein translation machinery (9). EMT can be initiated by microenvironmental signals such as TGF β , EGF, hypoxia, and tissue stiffness (10-13), and is effected through networks of EMT-transcription factor proteins (EMT-TFs) such as SNAIL, SLUG, TWIST1, ZEB1, SIX1, SOX10, and FOXC2 (14-18). These transcription regulators act in conjunction with epigenetic regulatory mechanisms such as histone post-translational modifications, re-organized large organized heterochromatin K9 modifications (LOCK) domains (19-22), DNA-methylation (21, 23, 24), and microRNAs including the miR-200 family (25-28) and miR-203 (29, 30) among others. Conversely MET stimulates the re-emergence of the epithelial phenotype, re-establishment of cell-cell contacts, a decrease in migratory traits, and re-expression of transcription factors such as ELF5, GRHL2, and OVOL1/2 (31-33).

Despite considerable overlap within the EMT-regulatory network, exogenous expression of individual EMT-TFs leads to distinctive EMT states (15, 34). Moreover, diverse partial- or hybrid-EMT, which express epithelial and mesenchymal traits have been recently described (35-40) and are reported to be highly plastic, efficiently initiate tumor growth (37), and indicate to poorer patient outcome (18, 40-44). Nevertheless, a multi-level analysis, including assessment of chromatin accessibility of cells experimentally induced to undergo EMT *and* MET has not been shown.

We endeavored to determine the genome-wide dynamics of chromatin accessibility at multiple timepoints during EMT and MET and characterize the relationship between chromatin accessibility, gene expression, and cell phenotype. Utilizing the assay for transposase-accessible chromatin with next-generation sequencing (ATAC-seq), we report that MCF10A mammary epithelial cells, proceeding through stepwise EMT and MET, undergo progressive and semi-reversible alterations in chromatin accessibility. By staggering the time of TGF β exposure and removal, we establish a series of partial states exhibiting distinct E-cadherin gene, transcript, and protein dynamics. Our analyses of chromatin accessibility in these states reveal that progression through EMT imparts a global increase in chromatin accessibility while MET is marked by chromatin compaction. We show that the chromatin insulator protein CTCF is a major participant in oscillating chromatin dynamics between EMT-induced and MET-resolved states and is required for preventing EMT-induced accumulation of the LOCK-domain associated mark, H3K9me3. Importantly, we find that initiation of EMT has the capacity to instill durable effects on the chromatin structure--most notably loss of accessibility at the E-cadherin promoter despite MET, potentially allowing the detection of past EMT events. Collectively our

findings indicate that activation of EMT and MET dramatically reconfigures chromatin organization with distinct effects dependent on the duration of EMT-inducing signal.

Results

TGF β induced morphological and transcriptomic dynamics

MCF10A human epithelial cells derived from spontaneously immortalized fibrocystic mammary tissue (45) have long been used as a model for epithelial-mesenchymal plasticity (46-49). To characterize progressive EMT/MET, we exposed cells to TGF β treatment and withdrawal for varying durations (50). The characteristic epithelial was lost at 2 days of TGF β treatment while typical spindle-like morphology emerged at 4 days of treatment (Fig. 1a). Notably, 4 days of TGF β withdrawal following a short-term treatment (4 days) elicited a rapid return to epithelial morphology (Fig. 1a) while 10 days of withdrawal was necessary to observe a return to epithelial morphology following long-term (10 days) treatment (Fig. 1a). To gauge the effect of varying durations of exposure to EMT-inducers, we continued to use both short-term treatment (4 days of TGF β , then withdrawal) and long-term treatment (10 days of TGF β , then withdrawal) models.

We next assessed changes in gene expression by RNA-seq. To measure broad changes in epithelial gene expression, we applied an epithelial-specific 76-gene score (76GS), where higher scores correspond to an epithelial gene expression pattern (51). TGF β treatment suppressed the 76GS score beginning at 2 days of treatment until 2 days following withdrawal whereupon it slowly recovered with additional withdrawal time (Fig. 1b). This analysis was followed by segmentation using a mammary cell-specific EMT gene expression signature (34). Gene expression data was selected for 50 genes universally upregulated by distinct models of EMT in HMLE mammary cells (34). In our model, EMT-Up genes increased expression at

different timepoints, indicating a phased implementation of gene activation (Fig. 1c). Excepting *CDH2*, the majority of EMT-Up core genes were rapidly suppressed. Withdrawal in from short-term treatment also facilitated a return to untreated levels of gene expression in most genes (Fig. 1c).

When examining regulation of individual genes, TGF β expectedly downregulated expression of epithelial-related genes such as *CDH1*, *EPCAM*, *OVOL2*, and *GRHL3* while withdrawal increased expression of these genes (Fig. 1d). *CDH3* (P-cadherin) a proposed partial-EMT marker (52) followed a similar pattern as *CDH1* (Fig 1d). We also characterized gene expression patterns of mesenchymal-related genes *CDH2*, *FN1*, *SNAI1/2*, *VIM*, and *ZEB1*, and observed upregulation following TGF β treatment and downregulation following withdrawal in both models (Fig. 1d).

Given the modest changes in the steady-state levels of *CDH1* mRNA, we profiled the dynamics of *CDH1* transcription regulation using a promoter reporter. MCF10A cells were transduced with the *CDH1* promoter linked to an RFP-encoding gene, facilitating promoter activity tracking at the single cell level (23). Commensurate with RNA-seq data, the *CDH1* promoter reporter remained active throughout the short-term TGF β treatment and withdrawal timecourse (Sup. Fig. 1a,b, Tables 1,2 pink panel). However, upon extended treatment, reporter-negative cells outnumbered reporter-positive cells, indicating promoter-induced repression (Sup. Fig. 1a,b, Tables 1,2 pink panel). Notably, the repression of the *CDH1* promoter was durable despite ten days of withdrawal.

We extended our observation of transcriptional dynamics during reversible EMT to microRNAs 200c and 203, which have been reported to target *ZEB1/2* mRNA (25, 53). In both models,

miR-200c and miR-203 decrease expression following 4 days of TGF β treatment and 10 days of TGF β treatment results in stronger suppression for both miRNAs (Fig 1e).

Our data demonstrate that individual gene expression dynamics follow distinct kinetics during reversible EMT. In particular, our model exhibited diminished total epithelial gene expression early during TGF β treatment, pointing to a partial-EMT state characterized by a modest decrease in *EPCAM* and *CDH1*, upregulation of *SNAI1/2*, and rapid activation of signaling effectors such as *POSTN* and *WNT5A*. During MET, a long-term TGF β -driven EMT is distinguished from short-term TGF β -driven EMT by a failure to re-activate *CDH1* promoter activity. Thus, within tumors, cells that do not express *CDH1* may be nevertheless undergoing MET.

TGF β induced protein dynamics

Many EMT-related genes are regulated by translation or protein localization (48, 54). Consequently, we assessed protein levels of EMT markers and EMT-TFs. We observed that TGF β induced suppression of E-cadherin and increased expression of mesenchymal markers N-cadherin and vimentin (Fig. 2a). In our short-term model, TGF β withdrawal led to protein expression typical of untreated cells, while long-term TGF β treatment led to more durable changes following withdrawal (Fig. 2a). For example, E-cadherin expression remained suppressed through 4 days of withdrawal and N-cadherin expression remained elevated through 10 days of withdrawal (Fig. 2a). Expression of the EMT-TF Slug increased within 4 hours of initiating TGF β treatment while expression of EMT-TFs Twist and ZEB1 did not emerge until later in the long-term TGF β treatment model (Fig. 2a), indicative of a progressive activation of EMT-TFs wherein partial-EMT is driven by Slug prior to expression of Twist and ZEB1.

Given the discordance between expression of *ZEB1* mRNA, upregulated at 2 days, and ZEB1 protein, detectable at 10 days, we next examined post-transcriptional regulation of *ZEB1* using a 3'UTR activity assay (23). MCF10A cells were transduced with a GFP-linked *ZEB1* 3'UTR reporter (GFP-Z1) and subjected to TGF β treatment. Concomitant with the suppression of miR-200c and miR-203 (Fig. 1e), 2 days of TGF β treatment was sufficient to observe elevated GFP-Z1 (Sup. Fig. 1a,b, green panel).

To better understand E-cadherin dynamics, we measured protein localization via immunofluorescence and FACS. Though the *CDH1*-RFP reporter indicated no changes in transcriptional activity in the short-term model (Sup. Fig. 1a,b, Tables 1,2), cell surface localization of E-cadherin was diminished at 4 days and remained low through 10 days of TGF β treatment (Fig. 2b, Sup. Fig. 1a,b, purple panel). Strikingly, during TGF β withdrawal, surface E-cadherin recovered in our short-term TGF β treatment model, but not in our long-term TGF β treatment model (Fig. 2b, Sup. Fig. 1a,b, purple panel). In the context of short-term TGF β treatment, RNA-seq, protein expression, and the *CDH1*-RFP reporter, (Fig. 1d, 2a, Sup. Fig. 1a,b) do not indicate increasing E-cadherin expression during TGF β withdrawal, while the immunofluorescence and FACS data (Fig. 2b, Sup. Fig. 1a,b) point to membrane localization. Such a recovery of surface E-cadherin suggests a cytoplasmic store capable of returning to the membrane following MET without the need for transcriptional upregulation. This finding is in concert with past studies on E-cadherin recycling (55).

In order to observe the relationship between TGF β -induced EMT, TGF β withdrawal-induced MET, and cellular plasticity, we characterized the mammosphere formation capacity of cells undergoing the long-term TGF β treatment and withdrawal time course. Consistent with the

observation that partial-EMT states exhibit maximal plasticity, seeding cells from such timepoints (4 days of treatment, or 10 days of treatment followed by 4 days of withdrawal) corresponded to significantly greater sphere formation than untreated cells or cells treated with TGF β for 10 days (Sup. Fig. 2). Thus, inducing partial-EMT and partial MET stimulates cellular plasticity and non-adherent growth properties associated with formation of mammospheres.

EMT and MET-induced chromatin accessibility regions

EMT is accompanied by reversible changes in the epigenome (19). Chromatin accessibility orchestrates dynamic gene expression by exposing or hiding regulatory genomic elements, resulting in distinct epigenomic states (56). To uncover the epigenomic basis associated with TGF β -driven reversible EMT, we performed the assay for transposase-accessible chromatin with next-generation sequencing (ATAC-seq) (57). Given the diverse transcriptional dynamics observed in EMT-related genes, we first examined chromatin accessibility at these loci.

Accessibility at *CDH1*, which remains high throughout TGF β treatment but diminishes during withdrawal, was strikingly different from accessibility at *EPCAM*, which diminished as soon as 2 days of TGF β (Fig. 3a, arrows). Notably, withdrawal in the short-term TGF β treatment was characterized by a recovery of *EPCAM* accessibility that was not present following withdrawal following long-term TGF β treatment (Fig. 3a, arrowhead). Additionally, *CDH3*, located immediately upstream of *CDH1*, follows similar accessibility patterns of *CDH1*, agreeing with observed protein expression patterns (Fig. 2a).

Accessibility at mesenchymal genes *CDH2* and *VIM* was more responsive to TGF β treatment and withdrawal. In both models, treatment stimulated new accessibility regions in *CDH2* and upstream of *VIM* and these regions diminished following withdrawal (Fig. 3b, arrow).

Interestingly, withdrawal following long-term TGF β treatment also resulted in the dissolution of

downstream ATAC-seq peaks previously prominent in untreated and TGF β -treated conditions (Fig. 3b, arrowhead).

We also observed subtle chromatin accessibility alterations at EMT-TF genes *ZEB1* and *SNAI1*. New ATAC-seq peaks emerged upstream of the *ZEB1* gene following 2 days of TGF β treatment (Fig. 3c, arrow). In both models, withdrawal diminished these peaks. *SNAI1* followed a similar pattern as upstream regions exhibited gains in accessibility following treatment which resolved, to a level lower than untreated cells, following withdrawal (Fig. 3c, arrowhead).

EMT and MET proceed through distinct global epigenomic stages

We next examined the changes in chromatin accessibility from a global perspective by enumeration of all chromatin accessibility regions detected in the two replicates (Fig. 3d) and limiting the analysis to regions shared between the replicate treatments (Fig. 3e). The extent of chromatin accessibility was highly dynamic across both treatment models. Generally, TGF β treatment was associated with greater chromatin accessibility while TGF β withdrawal was associated with diminished accessibility (Fig. 3d,e). Dramatically, 10 days of treatment led to 50% more accessible sites than untreated cells (175,103 vs 113,680 comparing both replicate regions and 97,714 vs 65,238 in common replicate regions). This state was reversed upon 4 days of TGF β withdrawal, whereupon nearly half of accessible sites were lost (91,335 sites comparing both replicate regions and 47,197 in common replicate regions) (Fig. 3d,e). Though the number of accessible chromatin regions fluctuated during reversible EMT, the regions remain similarly distributed amongst gene regulatory and intergenic loci (Fig. 3d,e). To stringently determine chromatin accessibility trends that accompany reversible EMT, we utilized regions common among both replicates for all subsequent analyses.

To determine if TGF β treatment resulted in the addition of new chromatin accessibility regions across the genome or near previously accessible sites, we interrogated the distance between ATAC-seq peaks and the number of ATAC-seq peak gaps exceeding 1 megabase (Mb). The median gap length was stable (medians 13,218-16,749 bp) throughout the timecourse with the exception of cells treated with TGF β for 10 days (median 11,564 bp) and 10 days of TGF β then withdrawal for 4 days (median 20,383 bp) (Fig. 4a). Concordantly, cells treated with TGF β for 10 days exhibited nearly half the number of >1Mb gaps as other timepoints and cells undergoing TGF β withdrawal had the most >1Mb gaps (Fig. 4b). Interestingly, when assessing the proximity of regions to known transcription start sites (TSSs), we observed that ATAC-seq peaks found in cells treated with TGF β are further away from known TSSs (Sup. Fig. 3a, Table 3). These findings support the notion that newly accessible regions associated with 10 days of TGF β treatment are being formed *de novo*, at locations distal to existing accessible regions, rather than clustered near to existing accessible regions.

Next, we assessed the similarities of chromatin accessibility profiles between timepoints using Pearson's correlation coefficient of log₂-transformed quantile-normalized peak scores. In both models, cells undergoing TGF β treatment co-clustered while cells undergoing TGF β withdrawal clustered together with untreated cells (Fig. 4c). The greatest distinctions in chromatin accessibility patterns were between the untreated and 2-day TGF β treated cells (in short-term model, R = 0.82) and between the untreated and 10-day TGF β treated cells (in long-term model, R = 0.81), suggesting that chromatin reprogramming occurs early, prior to many transcriptomic changes, and is sustained during EMT-induction. TGF β withdrawal rapidly reverts DNA accessibility patterns near to untreated conditions (R = 0.94 and R = 0.95 in short- and long-term, respectively) (Fig. 4c), demonstrating that the epigenome is highly responsive to TGF β treatment and withdrawal.

Intensity and adjacent gene function of global epigenomic changes

We next considered whether changes in the chromatin accessibility regions were at peaks with low scores ($\log_2$ [mean Peak Score] <3), moderate scores ($\log_2$ [mean Peak Score] $\geq 3, <5$), or high scores ($\log_2$ [mean Peak Score] ≥ 5), reasoning that, if timepoint-specific peaks were weak in intensity, the differences may be due to stochastic effects. When comparing untreated cells to cells exposed to TGF β for 4 days or 10 days, peaks with the greatest difference in peak score (non-grey circles) were among the those with low to moderate peak score intensity values (Fig. 4d, i, ii). Additionally, while TGF β results in an acquisition of new differentially-scored peaks, untreated conditions also contain some unique moderately-scored peaks which are lost following TGF β treatment (Fig. 4d, i, ii, dark gray). Interestingly, short-term, rather than long-term, TGF β treatment and withdrawal led to fewer differentially-scored peaks (Fig. 4d, iii, iv, light green and purple). When comparing untreated cells to cells that had undergone 10 days of TGF β withdrawal from either model, ATAC-seq peaks with the greatest peak score difference (non-grey circles) were among the peaks with the overall weakest intensity values (Fig. 4d, v, vi; Sup Fig. 3b). These data indicate that the epigenomic dynamics associated with EMT and MET create and remove significant novel chromatin accessibility sites. Additionally, these data suggest that the grade of EMT induction following withdrawal may stimulate distinct MET chromatin states and epigenomes.

To better understand the phased implementation of EMT-associated chromatin accessibility, we enumerated the overlapping ATAC-seq peaks. As expected, many chromatin accessibility regions in untreated cells are present at other timepoints ($n = 47,354$) (Sup Fig. 4a). However, TGF β treatment for any duration was associated with an additional 9,028 shared accessible regions, while a 10-day TGF β treatment yielded an additional 16,164 unique regions (Sup Fig.

4a). Interestingly, cells which had been exposed to TGF β , regardless of withdrawal time, retained some EMT-induced regions (Sup. Fig. 4b and 4c), despite the considerable chromatin constriction (Fig 3d,e). We then investigated the gene expression patterns of the subset of persistent EMT chromatin accessibility regions following long-term treatment and annotated the peaks to the closest gene and identified their gene expression patterns. Though chromatin accessibility was altered at these sites, most, but not all, gene expression returned to untreated conditions (Sup. Fig 4d, black box).

To derive the functional implications of these chromatin accessibility regions, we performed gene set enrichment analysis (GSEA) for the annotated genes closest to ATAC-seq peaks. msigDB hits revealed enrichment for Hallmark gene sets related to EMT, TNF- α signaling, hypoxia, and TGF β signaling as well as gene sets related to stemness and EMT in mammary cells or breast cancer (Sup. Fig. 5a, yellow). Enrichment of these gene sets diminishes following TGF β withdrawal (Sup. Fig. 5a, purple). We were also interested in the function of genes near sites which remained accessible despite TGF β withdrawal at our “Persistent EMT Peaks”. As above, this set was enriched for EMT, apical junction and mammary stemness genes (Sup. Fig. 5b). Notably, many of these genes remain expressed following 10 days of TGF β withdrawal (Sup. Fig. 4d), constituting a potential signature of past EMT events.

Dynamic transcription factor engagement during EMT and MET

We next hypothesized that TGF β treatment would modulate enrichment of transcription factor binding sites (TFBSs) to enable partial or full EMT. We used HOMER motif discovery analysis to determine the enrichment of TFBSs found within ATAC-seq peaks (58). The degree of significance for motif enrichment was highly variable in both models (Fig. 5a). Consistent with the TGF β -driven increase in the number of accessible sites (Fig. 3d), TGF β treatment drove an

increase in the overall significance of motif enrichment, which was diminished upon TGF β withdrawal (Fig. 5a). Notably, the motifs which are highly significant in TGF β -treated conditions were nonetheless enriched in other conditions (Sup. Fig 6a and b), indicating that introduction of novel TFBSs does not greatly contribute to the change in chromatin accessibility observed during reversible EMT.

We next wished to distinguish variation among individual transcription factors involved in progression through EMT and MET. We queried the percentage of 50-bp targets which contained the TFBS and limited our analyses to the top 20 enriched motifs. In both models, we noted considerable TGF β -driven increases in the prevalence of AP-1 family and SMAD-binding motifs which resolved to baseline during TGF β withdrawal (Fig. 5b). Because of the large range in TFBS prevalence, we calculated their percent change in comparison to untreated cells (Fig. 5c). While most TFBSs exhibited increased accessibility during TGF β treatment, we observed a tri-modal pattern of enrichment for CTCF and BORIS motifs, with distinct enrichment in samples that were untreated, experienced 10 days of TGF β , or experienced 10 days of TGF β withdrawal (Fig. 5b,c).

Loss of CTCF occupancy and protein accompanies partial-EMT and -MET states

CTCF and BORIS (*CTCF*) have some overlapping functions and participate in establishing topologically associated domains, genetic imprinting, and gene expression (59, 60). However, as BORIS is not expressed in breast cancers and mammary cell lines (61), we further investigated the pattern of dynamically-engaged CTCF binding motifs. The distance between engaged CTCF binding motifs remained stable during the initial phases of TGF β treatment but dropped significantly at 10 days of TGF β treatment, rose upon 4 days of TGF β withdrawal, and then stabilized to untreated levels at 10 days of withdrawal (Fig. 6a). As with the increase in

general chromatin accessibility (Fig. 4a), the pattern of accessible regions containing CTCF motifs was consistent with novel engagement of CTCF bindings sites across the genome rather than in clusters.

We next profiled the regulatory function of the target sites putatively occupied by CTCF. Ten days of TGF β treatment was characterized by an increase in the proportion of CTCF binding motifs at intergenic loci and a decrease in the proportion at promoters (Fig. 6b, bottom panel), further supporting the notion that CTCF is binding to sites across the genome. Additionally, the majority of CTCF motifs were found within 20 kb of the nearest TSS and the most considerable changes for CTCF binding were at locations between 10 kb and 1 Mb from TSSs (Fig. 6c,d). Consistent with the role of CTCF as a regulator of long-distance chromatin interactions, these data suggest that, during EMT and MET, CTCF dynamically engages gene-distal sites with potential regulatory effects.

In order to understand the potential functional impacts of altered CTCF binding, we performed GSEA for the genes nearest to dynamically engaged CTCF binding sites. In long-term reversible EMT, most genes adjacent to CTCF motifs were shared amongst the three conditions in which CTCF engagement was enriched ($n = 4,117$) however 10 days of TGF β treatment exhibited the largest number of characteristic genes ($n = 1,518$) (Sup. Fig. 7a). Interestingly, cells treated with TGF β appear to retain some remnants of CTCF reconfiguration despite withdrawal ($n=766$) (Sup. Fig. 7a), highlighting a possible residual effect of EMT/MET. GSEA also reveals a connection between genes nearest to CTCF sites and cell development and chromatin biology, as bivalent (H3K4me3+H3K27me3) domains were highly enriched (Sup. Fig. 7b, Table 6).

Differential CTCF engagement throughout a timecourse of TGF β treatment and withdrawal may be due to oscillations in CTCF expression. Despite considerable changes in motif enrichment, we note no changes in steady state *CTCF* mRNA levels (Fig. 7a). Conversely, western blotting revealed dynamic protein expression. In untreated conditions, Upon four days of TGF β treatment, CTCF expression decreases until around 8 days of withdrawal (Fig. 7b). Given the link between CTCF and both bivalent domains (Sup. Fig. 7b, Table 6) and LOCK domains, we assessed the global levels of relevant histone modifications. Concomitant with CTCF repression patterns, we also observed increases in H3K4-, H3K27-, and H3K9- trimethylation marks (Fig. 7b). We hypothesized that TGF β treatment could induce a proteasome-mediated degradation of CTCF, however treatment with TGF β and proteasome inhibitors did not rescue CTCF expression (data not shown). Collectively these data demonstrate that CTCF is dynamically regulated at the protein level during partial and reversible EMT and suggests that CTCF protein levels largely dictate the accessibility of CTCF binding motifs.

We sought to explore the implications of CTCF repression in EMT and MET induction. To do so, we generated doxycycline-inducible shRNA-expressing MCF10A cells to determine the effect of CTCF repression on EMT marker and histone modification levels. Surprisingly, CTCF repression alone was not sufficient to induce EMT in MCF10A cells, failing to alter the expression of E-cadherin or vimentin (Fig. 7c). However, CTCF repression was sufficient to increase global levels of H3K4me3 and H3K27me3 (Fig. 7d), corroborating the association between CTCF motifs and bivalent domains (Sup. Fig. 7b). Additionally, we noted increased H3K9me3 levels associated with TGF β -induced CTCF repression (Fig 7d), pointing to a potential effect on H3K9me3-mediated gene silencing in LOCK domains. Overall, these data demonstrate that CTCF protein, not mRNA, is dynamically regulated during long-term reversible EMT and that loss of CTCF drives alterations to the histone code.

Discussion

EMT and its reversal, MET, are important for normal physiological processes such as development and wound healing and is hypothesized to endow cancer cells with metastatic abilities. EMT has been revealed to progress through partial states in terms of morphology, gene expression, and expression of epithelial protein marker E-cadherin. In studies utilizing solid tumor models, it has been shown that cells within an intermediate-mesenchymal state are more spheroidogenic and resistant to anoikis (43) and cells that express both KRT14 and vimentin disproportionately contribute to metastasis (40). Despite this importance, the factors mediating the progression through partial-EMT states and back are not well characterized. In this study, we have extensively characterized the chromatin accessibility alterations and gene expression output that occur during distinct stages of reversible TGF β -induced EMT.

In our study, we demonstrate that short-term TGF β elicits dynamic trafficking of E-cadherin to and from the cell membrane. Four days of TGF β treatment reduces the proportion of cells with detectable surface E-cadherin despite a minor repression of overall E-cadherin protein or transcript. This finding corroborates a report by Aiello et al. who observed that pancreatic cancer cells with partial-EMT features exhibit high levels of intracellular E-cadherin which co-localizes with recycling endocytic vesicles (54). However upon 10 days of TGF β treatment we observed the emergence of cells which have not only lost membranous E-cadherin but show a diminishment in their total E-cadherin protein and *CDH1* accessibility. This finding was unexpected and suggests that persistent exposure to EMT-inducing stimuli imposes chromatin alterations that are not reversed despite withdrawal of the stimulus. While outside the bounds of the present study, EMT-induced DNA methylation has been implicated in stable mesenchymal-

like phenotypes by repression of miR-200b, miR-200c, miR-203 and other targets (20, 21, 23, 30, 62).

Transcriptomic determination of EMT status utilizing an EMT-specific gene expression signature has linked EMT enrichment to claudin-low breast cancers (34), mesenchymal glioblastoma (63), rapamycin-resistance in breast cancer (64), radio-resistance in prostate cancer (65), and response to immune checkpoint blockade therapy in lung cancer (66). (35, 44, 47, 54, 67). Herein, we show that transition through both EMT and MET involves stage-wise changes in EMT-signature gene expression. Moreover, TGF β -withdrawal from cells treated for only 4 days elicited changes in gene expression that largely mirrored patterns observed at 4 days of treatment. However, withdrawal following 10 days of TGF β treatment led to prolonged expression of N-cadherin and Twist and failure to fully re-express E-cadherin. These data are similar to those recently reported by Jia et al. who find that the ZEB1 3'UTR reporter remains expressed despite prolonged TGF β exposure and withdrawal (68). It has been also reported that partial-EMT states are coordinated by Slug (*SNAI2*) while Snail (*SNAI1*) and ZEB-1 activation can promote a mesenchymal phenotype (69). Our results agree with this observation, as Slug protein expression increases as early as 4 hours of TGF β exposure while ZEB1 protein expression is observed only following 10 days of TGF β and 4 days of withdrawal, at the time point which expresses the least amount of E-cadherin, *CDH1*, and *CDH1*-RFP activity.

We show that EMT is accompanied by dynamic increases in chromatin accessibility. These observations are in-line with prior observations of murine mammary epithelial cells in response to TGF β treatment (70). We note that striking chromatin alterations occur relatively rapidly following 2 days of TGF β as 22,354 nascent peaks appear while only 9,678 peaks are lost.

Many of the newly-acquired regions have low accessibility scores and may contribute to some of the stochastic transcriptional noise that permits cell plasticity(71). Overall TGF β withdrawal-induced MET causes a decrease in accessibility inducing a global chromatin “shutdown” whereupon the number of accessible regions is reduced by half and the distance between remaining regions significantly increases.

We identify that several factors increase their degree of chromatin engagement including SMAD and AP-1 transcription factors, which have been previously reported to mediate and be regulated by EMT (39, 40, 48, 70, 72). We interpret these results to suggest that chromatin is highly responsive to TGF β treatment, permitted through numerous relatively weak interactions between a broad set of DNA-binding proteins that create a permissive chromatin environment. Following TGF β withdrawal, these DNA-binding proteins lack the signals to sustain their occupancy, and the chromatin compacts until the cell re-establishes epigenetic homeostasis similar to baseline conditions,

Though most transcription factors were responsive to TGF β treatment or withdrawal, interestingly we observed tri-modal enrichment of CTCF motifs and declines during transitional, or partial-EMT and -MET states. CTCF participates in gene expression regulation, chromatin organization and genetic imprinting. In cancer, CTCF-binding sites have been found to be mutated in solid tumors (59, 60) and methylation at CTCF binding elements has been shown to drive overexpression of oncogenes such *PDGFRA*(73). This dynamic enrichment is potentially driven by fluctuations in CTCF protein expression or stability. Notably, Pastushenko et al., which describes extant populations of cells in partial EMT states, applied ATAC-seq to highly characterized, sorted populations of epithelial (Epcam+), mesenchymal (CD106⁺/CD51⁺/CD61⁺), and intermediate (CD51⁻/CD61⁻) SCC cells (40). Motif enrichment

analysis of ATAC-seq data from Pastushenko et al. also demonstrates enrichment for CTCF binding motifs in accessible sites in epithelial and highly-mesenchymal states and a reduction in enrichment in partial-EMT states (40). Additionally CTCF has been shown in ovarian cancer to promote cancer metastasis by increasing the expression of genes such as *CTBP1*, *SERPINE1*, and *SRC* (74); however we did not observe accessible CTCF motifs adjacent to these genes in our model. A recent report by Li et al. demonstrates that an alternatively-spliced variant of CTCF can occupy canonical CTCF sites and cause differential effects on chromatin architecture gene expression (75). Therefore, it would be interesting to distinguish if alternatively-spliced variants of CTCF participate in partial stages and account for divergent effects observed between our model and others.

Conclusions

In conclusion, our study characterizes 1) E-cadherin expression and localization dynamics, 2) partial-EMT/MET gene expression, 3) chromatin alterations occurring during reversible EMT, 4) expression patterns and motif enrichment of CTCF, and 5) the link between CTCF repression and histone modifications. We conclude that E-cadherin dynamics are distinct in partial-EMT and partial-MET, and that CTCF loss facilitates chromatin reorganization in partial-EMT/MET states while re-expression drives the establishment of novel chromatin arrangements leading to altered gene regulation in both EMT and MET conditions, linking CTCF dynamics to epithelial-mesenchymal plasticity.

Methods

Cell culture

MCF10A cells (ATCC) were cultured in DME/F12 media (GE Healthcare Life Sciences) supplemented 5% horse serum (GE Healthcare Life Sciences), 1% penicillin/streptomycin

(Lonza), 20 ng/mL EGF (Sigma), 10 ng/mL insulin (Sigma), 500 ng/mL hydrocortisone (Acros Organics), and 100 ng/mL cholera toxin (Enzo Life Sciences). Cells were plated at 10,000 cells/cm² and passaged every other day to maintain consistent densities. For TGFβ treatment, media was supplemented with 5 ng/mL recombinant human TGFβ-1 (R&D Systems; resuspended in 4 mM HCl, 0.1% BSA).

Viral transductions

Stable Z-cad reporter cell lines were generated via viral transfection as described (23). In short, MCF10A cells were dually transduced with pHAGE-E-cadherin-RFP and FUGW-d2GFP-ZEB1 3' UTR lentiviruses packaged by transfected HEK-293T cells. RFP⁺/GFP⁺ doubly labeled MCF10A cells were sorted via FACSMelodyTM Cell Sorter (BD Biosciences).

For viral transfection of doxycycline-inducible shCTCF and shCtrl cell lines, HEK-293T cells (ATCC) were cultured in DMEM (Corning) supplemented with 10% FBS (Equitech-Bio) and 1% penicillin/streptomycin (Lonza). Virus DNA liposomes were prepared using FuGENE HD Transfection reagent (Promega) and DMEM. Vector-expressing cells were selected with 10 µg/mL puromycin.

Western blotting

Cells were harvested and resuspended in RIPA buffer (Alfa Aesar) supplemented with protease and phosphatase inhibitors (ThermoScientific) and incubated in ice for 60 minutes. Lysed cells were centrifuged at 15,000 rcf for 20 minutes at 4° C and the supernatant was isolated.

Protein concentrations were determined using a bicinchoninic acid assay (ThermoScientific).

Approximately 40 µg of protein per treatment was loaded into a 12% SDS-polyacrylamide gel and run at 125 V for 90 minutes. Following electrophoresis, gels were transferred to methanol-

activated PVDF membranes (Thermo Scientific) for 2.5 hours at 0.250 A, and blots were blocked in 5% milk (Carnation) in TBST for 30 minutes at room temperature. Primary antibodies were incubated overnight at 4°C and secondary antibodies were incubated at room temperature for 1 hour. Chemiluminescence signal was obtained using ECLTM Prime (GE Healthcare) and blot images were generated using the ChemiDocTM Imaging System (Bio-Rad).

Flow cytometry

At the conclusion of the timecourse, 2.5×10^6 Z-CAD reporter cells were counted and resuspended in 500 μ L 1% FBS (Equitech-Bio) in PBS with anti-E-cadherin BV421 (#745965, 1:100, BD Biosciences) and incubated on ice for 90 minutes. Following incubation, cells were pelleted and washed twice with 1% FBS in PBS and subjected to flow cytometry using a FACSMelodyTM (BD Biosciences).

Immunostaining

Live cells plated on glass coverslips were fixed with 2% paraformaldehyde (Acros Organic) in PBS (Lonza) for 20 minutes at room temperature, followed by washing with PBS. Fixed tissues were permeabilized with 0.3% Triton X-100 (Fisher Bioreagents) in PBS for 15 minutes followed by a series of PBS washes. Cells were quenched with 1% glycine (Fisher Bioreagents) in PBS, washed with PBS, and blocked in 8% BSA (Alfa Aesar) in TBST at 4°C overnight. Coverslips were incubated in primary antibody at 4°C overnight. Following incubation, coverslips were washed in TBST and subjected to secondary antibody dilution for 1 hour at room temperature. Nuclei were stained with DAPI for 5 minutes, washed with DNase and RNase-free water, then affixed to glass slides with Permount (Fisher Scientific).

Brightfield imaging was performed using a Nikon Eclipse Ts2R microscope with DS-Qi2 camera and analyzed, scaled, and edited using Nikon NIS Elements v4.5 Imaging Software. Confocal immunofluorescence imaging was performed using an Olympus FV-3000 Confocal Laser Scanning Microscope and analyzed, scaled, and edited using Olympus FV31S-SW software. Image cropping was performed using ImageJ (version 1.51s).

Antibodies

The following antibodies and dilutions (in 5% milk in TBST) were used for western blotting: E-cadherin (#14472, monoclonal mouse, 1:1000, Cell Signaling), N-cadherin (#13116, monoclonal rabbit, 1:1000, Cell Signaling), P-cadherin (#2189, monoclonal rabbit, 1:1000, Cell Signaling), Vimentin (#10366-1-AP, polyclonal rabbit, 1:2000, ProteinTech), Slug (#9585, monoclonal rabbit, 1:1000, Cell Signaling), CTCF (#07-729, polyclonal rabbit, 1:1000, Millipore Sigma), Actin (#612656, monoclonal mouse, 1:2000, BD Biosciences), rabbit HRP-linked IgG secondary (#7074S, 1:2000 Cell Signaling), mouse HRP-linked IgG secondary (#926-80010, 1:2000, Li-Cor).

The following antibodies and dilutions (in TBST for primary or 3% BSA in TBST for secondary) were used for immunofluorescence: E-cadherin (#14472, monoclonal mouse, 1:100, Cell Signaling), mouse-IgG Alexa Fluor 594-conjugated secondary (#8890, 1:100,000, Cell Signaling).

RNA extraction and qPCR

RNA was extracted from cell cultures using TriZol Reagent (Thermo Fisher) and isolated following manufacturer guidelines. 500 ng of RNA was used for input for cDNA synthesis using miR-203, miR-200c, and U6-specific TaqMan Gene Expression primers (Applied Biosystems).

Quantitative PCR analyses were performed using cDNA as a template, TaqMan-specific qPCR primers, and TaqMan Gene Expression Master Mix (Applied Biosystems). QuantStudio5 real-time PCR machine (Applied Biosystems) with four technical replicates per biological replicate. Signal was quantified and normalized using QuantStudios5 software (version 1.5.1).

Mammosphere Assays

At the conclusion of the timecourse, 5×10^3 cells were plated in low-attachment 96-well plates containing 100 μ L MEGM media (without BPE) (Lonza, CC-3150), 20 ng/mL bFGF (Sigma Aldrich), 10 ng/mL EGF (Sigma Aldrich), 4 μ g/mL heparin (Sigma Aldrich), and 1% methylcellulose. 25 μ L mammosphere media was added to each well every third day. Spheres were allowed to form for 14 days.

RNA-seq Library Preparation and Sequencing

RNA was extracted from cell cultures using TriZol Reagent (Thermo Fisher) and isolated following manufacturer guidelines. Libraries were prepared using TruSeq Stranded mRNA Library Prep Kit (Illumina).

EMT score calculation

The EMT scores were calculated utilizing the 76-gene expression signature reported (51) and the metric mentioned based on that gene signature (76). For each sample, the score was calculated as a weighted sum of 76 gene expression levels, and weights were measured based on the correlation of a particular gene with CDH1 expression. The scores were standardized for all the samples in the dataset by subtracting the mean across samples so that the global mean of the score was zero. Negative scores calculated using this method can be interpreted as mesenchymal phenotype and the positive scores as epithelial.

ATAC-seq Library Preparation and Sequencing

ATAC-seq libraries were generated as previously described (57). Briefly stated, 5×10^4 cells obtained from cell culture, centrifuged and cell pellets were resuspended in 50 μ L lysis buffer (10 mM Tris , 10 mM NaCl , 3 mM MgCl_2 , and 0.1% IGEPAL CA-630) and centrifuged at $500g$ for 10 min at 4°C . The pellet was resuspended in transposase reaction mix (25 μ L 2X TD buffer, 2.5 μ L Transposase (Nextera DNA sample preparation kit, Illumina), and 22.5 μ L H_2O) and incubated at 37°C for 30 min. Tagmented DNA was purified using MinElute PCR Purification Kit (Qiagen) per manufacturer's instructions. DNA libraries were PCR-amplified using Nextera DNA Sample Preparation Kit (Illumina) using the following PCR conditions: 98°C for 30s, then thermocycling for 98°C for 10s, 63°C for 30s, and 72°C for 1 min for 12 cycles followed by 72°C for 5 min. PCR products were size-selected for 200 to 800 base pair fragments using SPRI-Select Beads (Beckmann-Coulter). ATAC-seq reads were paired-end sequenced using an Illumina NextSeq500.

ATAC analysis

Due to the similarities of both ends, only one paired-end read was used for analysis. Adapter sequences were removed using cutadapt (Galaxy version 1.16.6) and reads were cropped to 30 bp with Trimmomatic (Galaxy Version 0.36.6). ATAC-seq reads were aligned to *hg19* using Bowtie2 (v2.3.4.2). Mitochondrial, unmapped and random contigs, and ChrY reads were excluded using samtools (v1.9) (77) to generate filtered bam files.

Tag directories were generated in HOMER from filtered bam files (58). Peaks from each replicate were called separately using HOMER by calling 'findPeaks [Tag Directory] -style

dnase -o auto.’ Following, replicate peaks were merged by calling ‘mergePeaks -d 300 [Rep 1] [Rep 2]’ to determine common peaks. Common peaks were used for downstream analyses.

For Pearson correlation analyses, combined tag directories containing both replicates were generated to quantify average peak score. Common merged peaks from each replicate were merged with other time course conditions by calling ‘mergedPeak -d 300 [Peak files].’ Time course peak files were annotated and quantified to hg19 by calling “annotatePeaks.pl [Merged Peak file] hg19 -size 300 -log -d.” Peak scores for each condition were quantile-normalized by the preprocessCore package (v1.44.0) in R (v3.5.1). Quantile-normalized Pearson correlation scores were generated by R Base and visualized by the pheatmap R package (v1.0.12).

De novo and known motif searches were performed using HOMER (Heinz et al., 2010) for 50 basepair regions excluding masked genomic regions by calling ‘findMotifsGenome.pl [Common peaks] hg19 -size 50 -mask.” Motifs with p-values $> 10^{-12}$ were discarded. Plots representing the number of significant motifs (p-value $\leq 10^{-12}$) and their enrichment were generated using the ggplot2 R package (3.2.0).

Venn Diagrams and GSEA analysis

Peak similarities were identified using mergePeaks in HOMER and annotated to *hg19* to produce the Entrez IDs for the gene promoters nearest to peaks. Entrez IDs were input in Venn Diagram tool (<http://bioinformatics.psb.ugent.be/webtools/Venn/>) to enumerate similarities. Accessed 11 November 2019. LucidChart was used to produce Venn Diagrams. GSEA analysis for MSigDB hits was performed for specific peak groups. Because of the abundance of MSigDB hits, our analysis was limited to either unbiased Hallmarks-only gene sets (78), or breast and mammary-specific gene sets (containing keywords “breast” or “mammary”).

Primers

The following primers were used for ATAC sequencing:

N501: AATGATACGGCGACCACCGAGATCTACACTAGATCGCTCGTCGGCAGCGTC

N502: AATGATACGGCGACCACCGAGATCTACACCTCTCTATTTCGTCGGCAGCGTC

N701: CAAGCAGAAGACGGCATAACGAGATTCGCCTTAGTCTCGTGGGCTCGGAGATGT

N702: CAAGCAGAAGACGGCATAACGAGATCTAGTACGGTCTCGTGGGCTCGGAGATGT

N703: CAAGCAGAAGACGGCATAACGAGATTTCTGCCTGTCTCGTGGGCTCGGAGATGT

N704: CAAGCAGAAGACGGCATAACGAGATGCTCAGGAGTCTCGTGGGCTCGGAGATGT

N707: CAAGCAGAAGACGGCATAACGAGATGTAGAGAGGTCTCGTGGGCTCGGAGATGT

N708: CAAGCAGAAGACGGCATAACGAGATCCTCTCTGGTCTCGTGGGCTCGGAGATGT

N710: CAAGCAGAAGACGGCATAACGAGATCAGCCTCGGTCTCGTGGGCTCGGAGATGT

N711: CAAGCAGAAGACGGCATAACGAGATTGCCTCTTGTCTCGTGGGCTCGGAGATGT

N712: CAAGCAGAAGACGGCATAACGAGATTCCTCTACGTCTCGTGGGCTCGGAGATGT

Quantification and Statistical analysis

Two-tailed Student's *t*-test and ANOVA were performed using GraphPad Prism (v6) and R (v 3.5.1).

Availability of data and materials

The ATAC and RNA sequencing data generated during the current study are available in the NCBI Gene Expression Omnibus (GEO) and are accessible through GEO series accession number GSE145851 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145851>).

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing Interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Collaborative Faculty Research Investment Program (30300179) and the Susan G. Komen Foundation Career Catalyst Research Grant (CCR18548469) to J.H.T. M.K.J. was supported by Ramanujan Fellowship awarded by Science and Engineering Board (SERB), Department of Science and Technology (DST), and the Government of India (SB/S2/RJN-049/2018).

Author Contributions

J.H.T. and Y.L. conceived, managed, and arranged funding for the project; J.H.T. and K.S.J. designed the experiments; K.S.J. performed most of the experiments and performed ATAC- and RNA-seq bioinformatics analysis; S.H., P.C., and M.K.J. provided computational analysis for RNA-seq; S.S. assisted with quantitative PCR data; K.S.J. and M.J.T. contributed to the Z-CAD transduced cells used in this study; Y.L. provided training and guidance with bioinformatic analyses. J.H.T. and K.S.J. wrote the manuscript. All authors read and approved the final draft of the manuscript.

Acknowledgements

We thank Dr. Dwayne Simmons for generously permitting the use of his lab materials. We thank Dr. Michelle Nemec and the Baylor University Molecular Biosciences Center for support during the course of this work. We would like to thank Dr. Bernd Zechmann (Center for Microscopy and Imaging, Baylor University, Waco, TX) for technical support during microscopy and image analysis.

Competing Interests

The authors declare no competing interests.

Figure Legends

Fig. 1 Phased gene expression changes during TGF β treatment and withdrawal. **a** Brightfield photomicrographs of MCF10A cells at indicated durations of 5 ng/mL TGF β treatment and withdrawal in short-term (left) and long-term (right) TGF β -induced EMT models. Scale bars = 80 μ m. mRNA expression patterns based on the: **b** 76-Gene Epithelial Metric (51), and **c** log₂FPKM expression of Core EMT Signature (34) in matched replicate (n = 1). **d** mRNA expression of select epithelial and mesenchymal genes as defined by RNA-seq in short-term (top) and long-term (bottom) models (n = 2, mean $\pm$ SEM). **e** Expression of miR-200c (red) and miR-203 (green) during short-term (left) and long-term (right) models. Data were normalized using sno-U6 and shown as mean + SEM from n = 4 with the indicated significance by using a two-tailed Student's *t* test, statistical comparisons shown in table to the right of graph. ns = not significant, **p* $\leq$ 0.05, ***p* $\leq$ 0.01, *****p* < 0.0001

Fig. 2 Protein expression dynamics during TGF β treatment and withdrawal. **a** Western blot for epithelial and mesenchymal markers in MCF10A cells at indicated durations of 5 ng/mL TGF β treatment and withdrawal in short-term (left) and long-term (right) TGF β -induced EMT models. Table representing normalized values (relative to treatment loading and compared to untreated protein expression, respectively) shown to the right of graphs. **b** Representative confocal micrographs of E-cadherin localization (red) relative to nuclei (DAPI, blue) in short-term (top) and long-term (bottom) models. Scale bar = 30 μ m.

Fig. 3 Dynamics of EMT- and MET-induced chromatin accessibility. ATAC-seq peak profiles of select: **a** epithelial (EPCAM, *CDH3*, and *CDH1*), **b** mesenchymal (*CDH2* and *VIM*), and **c** EMT-TF (*ZEB1* and *SNAI1*) genes in short-term (top) and long-term (bottom) TGF β -induced EMT models (n = 2). Arrows and arrowheads indicate regions of interest. Number of accessible chromatin regions for **d** combined replicate peaks (top) and gene annotation proportions (bottom) in short-term (left) and long-term (right) models, and **e** number of peaks common among treatment replicates (top) and their gene annotation proportions (bottom) among replicates in short-term (left) and long-term (right) models (n = 2).

Fig. 4 Differential accessibility is driven by changes at low- to moderately-accessible sites across the genome. **a** Gap length distribution (in bp) between ATAC peaks common among replicates in short-term (left) and long-term (right) TGF β -induced EMT models. Data were analyzed using two-way ANOVA using Tukey's multiple comparison test, statistical comparisons shown in table below graphs, ns = not significant, * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p < 0.0001$. **b** Number of gaps between peaks common among replicates that exceed 1Mb in short-term (top) and long-term (bottom) models. **c** Pearson's correlation analysis on quantile-normalized log-transformed ATAC peaks common among replicates in short-term

(top) and long-term (bottom) models. **d** Differential accessibility ($\log_2$ fold change in reads per 300-bp region) among selected EMT-induced and EMT-withdrawn conditions in short-term (top three) and long-term (bottom bottom) models. Colored peaks represent peaks at least 4-fold more accessibility at the indicated conditions. Dark gray = untreated, blue = 4d +TGF β , light green = 4d +TGF β , 10d -TGF β , yellow = 10d +TGF β , and purple = 10d +TGF β , 10d -TGF β .

Fig. 5 TFBS dynamics associated with increased accessibility and partial states. **a** Motif enrichment distribution for highly-significant ($p \leq 10^{-12}$) motifs in short-term (left) and long-term (right) TGF β -induced EMT models. **b** Motif enrichment by percentage of 50-bp targets containing motif of the top 20 differentially-enriched motifs in short-term (left) and long-term (right) models. **c** Motif enrichment percent change from untreated of top 20 differentially-enriched motifs in short-term (left) and long-term (right) models.

Fig. 6 CTCF dynamic engagement is responsible for increased intergenic accessibility. **a** Gap length distribution (in bp) between ATAC peaks containing CTCF motifs (left). Table representing statistical comparisons (right). Data were analyzed using two-way ANOVA using Tukey's multiple comparison test, statistical comparisons shown in table to the right of graph, **** $p < 0.0001$. **b** Table representing maximum, minimum, mean, and median bp distance from TSS for CTCF motif-containing accessible regions of peaks common among replicates in long-term model. **c** Number of accessible chromatin regions containing CTCF motifs (top) and their gene annotation proportion (bottom) in long-term model. **d** CTCF motif distance from TSS (in bp) for peaks containing CTCF motif (top) and their gene annotation proportion (bottom) in long-term model.

Fig. 7 CTCF protein and histone modifications are dynamically expressed during reversible EMT and CTCF repression is accompanied by upregulation of H3K9me3 marks. **a** Average $\log_2$ FPKM counts for *CTCF* gene based on RNA-seq in short-term (left, lime green) and long-term (right, purple) TGFB-induced EMT model ($n = 2$, mean $\pm$ SEM). **b** Western blot for CTCF, E-cadherin, and various H3 post translational modifications in long-term reversible EMT model. **c** Western blot for protein expression for epithelial and mesenchymal markers and histone tail modification expression following 3d 0.5 μ g/mL doxycycline on inducible short hairpin CTCF knockdown or non-targeting control in MCF10A cells. **d** Western blot for protein expression for epithelial and mesenchymal markers and indicated histone H3 post-translational modifications following 4 days of 0.5 μ g/mL doxycycline on inducible short hairpin CTCF knockdown or non-targeting control in MCF10A cells.

REFERENCES

1. Nieto MA, Huang RYJ, Jackson RA, Thiery JP. Emt: 2016. *Cell*. 2016;166(1):21-45.
2. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell*. 2004;117(7):927-39.
3. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(24):10069-74.
4. Xue CS, Plieth D, Venkov C, Xu C, Neilson EG. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. *Cancer research*. 2003;63(12):3386-94.
5. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. *Cancer cell*. 2012;22(6):725-36.
6. Tran HD, Luitel K, Kim M, Zhang K, Longmore GD, Tran DD. Transient SNAIL1 Expression Is Necessary for Metastatic Competence in Breast Cancer. *Cancer research*. 2014;74(21):6330-40.
7. Xu YX, Lee DK, Feng Z, Xu Y, Bu W, Li Y, et al. Breast tumor cell-specific knockout of Twist1 inhibits cancer cell plasticity, dissemination, and lung metastasis in mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(43):11494-9.
8. Revenco T, Nicodeme A, Pastushenko I, Sznurkowska MK, Latil M, Sotiropoulou PA, et al. Context Dependency of Epithelial-to-Mesenchymal Transition for Metastasis. *Cell Rep*. 2019;29(6):1458-+.
9. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Bio*. 2014;15(3):178-96.
10. Miettinen PJ, Ebner R, Lopez AR, Derynck R. Tgf-Beta Induced Transdifferentiation of Mammary Epithelial-Cells to Mesenchymal Cells - Involvement of Type-I Receptors. *J Cell Biol*. 1994;127(6):2021-36.
11. Kim K, Lu ZF, Hay ED. Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. *Cell Biol Int*. 2002;26(5):463-76.
12. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1 alpha promotes metastasis. *Nature cell biology*. 2008;10(3):295-305.
13. Leight JL, Wozniak MA, Chen S, Lynch ML, Chen CS. Matrix rigidity regulates a switch between TGF-beta 1-induced apoptosis and epithelial-mesenchymal transition. *Molecular biology of the cell*. 2012;23(5):781-91.
14. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. *Nature reviews Cancer*. 2013;13(2):97-110.
15. Stemmler MP, Eccles RL, Brabletz S, Brabletz T. Non-redundant functions of EMT transcription factors. *Nature cell biology*. 2019;21(1):102-12.
16. Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. *Cancer research*. 2013;73(6):1981-92.
17. Dravis C, Spike BT, Harrell JC, Johns C, Trejo CL, Southard-Smith EM, et al. Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells. *Cell Rep*. 2015;12(12):2035-48.
18. Dravis C, Chung CY, Lytle NK, Herrera-Valdez J, Luna G, Trejo CL, et al. Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity. *Cancer cell*. 2018;34(3):466-+.

19. Taube JH SN, Johnson KS, Reisenauer KN, Nesbit TA, Joseph R, Vijay GV, Sarkar TR, Bhangre NA, Song JJ, Chang JT, Lee MG, Soundararajan R, Mani SA. The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition. *Oncotarget*. 2017.
20. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. *Nat Struct Mol Biol*. 2011;18(8):867-U21.
21. Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, et al. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. *Genome biology*. 2013;14(12):R144.
22. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. *Nat Struct Mol Biol*. 2011;18(8):867-74.
23. Toneff MJ, Sreekumar A, Tinnirello A, Hollander PD, Habib S, Li S, et al. The Z-cad dual fluorescent sensor detects dynamic changes between the epithelial and mesenchymal cellular states. *BMC Biol*. 2016;14:47.
24. Lombaerts M, van Wezel T, Philippo K, Dierssen JWF, Zimmerman RME, Oosting J, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. *Brit J Cancer*. 2006;94(5):661-71.
25. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. *Cancer research*. 2008;68(19):7846-54.
26. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. *EMBO reports*. 2008;9(6):582-9.
27. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nature cell biology*. 2008;10(5):593-601.
28. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes & development*. 2008;22(7):894-907.
29. Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z, et al. Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells. *Genes & cancer*. 2011;2(8):782-91.
30. Taube JH, Malouf GG, Lu E, Sphyris N, Vijay V, Ramachandran PP, et al. Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. *Scientific reports*. 2013;3:2687.
31. Chakrabarti R, Hwang J, Blanco MA, Wei Y, Lukacisin M, Romano RA, et al. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. *Nature cell biology*. 2012;14(11):1212-+.
32. Ray HJ, Niswander LA. Grainyhead-like 2 downstream targets act to suppress epithelial-to-mesenchymal transition during neural tube closure. *Development*. 2016;143(7):1192-204.
33. Roca H, Hernandez J, Weidner S, McEachin RC, Fuller D, Sud S, et al. Transcription Factors OVOL1 and OVOL2 Induce the Mesenchymal to Epithelial Transition in Human Cancer. *PloS one*. 2013;8(10).
34. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. *Proceedings of the National Academy of Sciences*. 2010;107(35):15449-54.

35. Grosse-Wilde A, Fouquier d'Herouel A, McIntosh E, Ertaylan G, Skupin A, Kuestner RE, et al. Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival. *PloS one*. 2015;10(5):e0126522.
36. Jolly MK, Boareto M, Huang B, Jia DY, Lu MY, Ben-Jacob E, et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. *Frontiers in Oncology*. 2015;5.
37. Bierie B, Pierce SE, Kroeger C, Stover DG, Pattabiraman DR, Thiru P, et al. Integrin-beta4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(12):E2337-E46.
38. McFaline-Figueroa JL, Hill AJ, Qiu XJ, Jackson D, Shendure J, Trapnell C. A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition. *Nature Genetics*. 2019;51(9):1389-+.
39. Meyer-Schaller N, Cardner M, Diepenbruck M, Saxena M, Tiede S, Luond F, et al. A Hierarchical Regulatory Landscape during the Multiple Stages of EMT. *Developmental Cell*. 2019;48(4):539-+.
40. Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. Identification of the tumour transition states occurring during EMT. *Nature*. 2018;556(7702):463-8.
41. Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. *Cell*. 2017;171(7):1611-24 e24.
42. Cook DP, Vanderhyden BC. Comparing transcriptional dynamics of the epithelial-mesenchymal transition. *bioRxiv*. 2019.
43. Huang RYJ, Wong MK, Tan TZ, Kuay KT, Ng AHC, Chung VY, et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). *Cell death & disease*. 2013;4.
44. George JT, Jolly MK, Xu SN, Somarelli JA, Levine H. Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. *Cancer research*. 2017;77(22):6415-28.
45. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, Mcgrath CM, et al. Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial-Cell Line, MCF-10. *Cancer research*. 1990;50(18):6075-86.
46. Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM, et al. Vimentin contributes to human mammary epithelial cell migration. *Journal of Cell Science*. 1999;112(24):4615-25.
47. Zhang JY, Tian XJ, Zhang H, Teng Y, Li RY, Bai F, et al. TGF-beta-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. *Sci Signal*. 2014;7(345).
48. Chaudhury A, Cheema S, Fachini JM, Kongchan N, Lu GJ, Simon LM, et al. CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. *Nature communications*. 2016;7.
49. Liu YW, Xue MZ, Du SW, Feng WW, Zhang K, Zhang LW, et al. Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT (vol 10, 1637, 2019). *Nature communications*. 2019;10.
50. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. *Cell Res*. 2009;19(2):156-72.
51. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2013;19(1):279-90.
52. Ribeiro AS, Paredes J. P-cadherin linking breast cancer stem cells and invasion: a promising marker to identify an "intermediate/metastable" EMT state. *Frontiers in Oncology*. 2015;4.

53. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. *Nature cell biology*. 2009;11(12):1487-95.
54. Aiello NM, Maddipati R, Norgard RJ, Balli D, Li JY, Yuan S, et al. EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. *Developmental Cell*. 2018;45(6):681-+.
55. Le TL, Yap AS, Stow JL. Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics. *J Cell Biol*. 1999;146(1):219-32.
56. Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the regulatory epigenome. *Nature Reviews Genetics*. 2019;20(4):207-20.
57. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nature methods*. 2013;10(12):1213-+.
58. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell*. 2010;38(4):576-89.
59. Katainen R, Dave K, Pitkanen E, Palin K, Kivioja T, Valimäki N, et al. CTCF/cohesin-binding sites are frequently mutated in cancer. *Nature Genetics*. 2015;47(7):818-+.
60. Kaiser VB, Taylor MS, Semple CA. Mutational Biases Drive Elevated Rates of Substitution at Regulatory Sites across Cancer Types. *PLoS genetics*. 2016;12(8).
61. Hines WC, Bazarov AV, Mukhopadhyay R, Yaswen P. BORIS (CTCF-L) is not expressed in most human breast cell lines and high grade breast carcinomas. *PloS one*. 2010;5(3):e9738.
62. Cui H, Hu Y, Guo DD, Zhang AF, Gu YJ, Zhang SD, et al. DNA methyltransferase 3A isoform b contributes to repressing Ecadherin through cooperation of DNA methylation and H3K27/H3K9 methylation in EMT-related metastasis of gastric cancer. *Oncogene*. 2018;37(32):4358-71.
63. Zarkoob H, Taube JH, Singh SK, Mani SA, Kohandel M. Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein. *PloS one*. 2013;8(5):e64169.
64. Holder AM, Akcakanat A, Adkins F, Evans K, Chen HQ, Wei CM, et al. Epithelial to mesenchymal transition is associated with rapamycin resistance. *Oncotarget*. 2015;6(23):19500-13.
65. Stark TW, Hensley PJ, Spear A, Pu H, Strup SS, Kyprianou N. Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance. *Prostate*. 2017;77(16):1583-91.
66. Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, et al. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. *Lung Cancer*. 2020;139:1-8.
67. Harner-Foreman N, Vadakekolathu J, Laversin SA, Mathieu MG, Reeder S, Pockley AG, et al. A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics. *Scientific reports*. 2017;7.
68. Jia W, Deshmukh A, Mani SA, Jolly MK, Levine H. A possible role for epigenetic feedback regulation in the dynamics of the epithelial-mesenchymal transition (EMT). *Phys Biol*. 2019;16(6):066004.
69. Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. *Nature*. 2015;525(7568):256-60.
70. Arase M, Tamura Y, Kawasaki N, Isogaya K, Nakaki R, Mizutani A, et al. Dynamics of chromatin accessibility during TGF-beta-induced EMT of Ras-transformed mammary gland epithelial cells. *Scientific reports*. 2017;7(1):1166.

71. Pujadas E, Feinberg AP. Regulated Noise in the Epigenetic Landscape of Development and Disease. *Cell*. 2012;148(6):1123-31.
72. Latil M, Nassar D, Beck B, Boumahdi S, Wang L, Brisebarre A, et al. Cell-Type-Specific Chromatin States Differentially Prime Squamous Cell Carcinoma Tumor-Initiating Cells for Epithelial to Mesenchymal Transition. *Cell Stem Cell*. 2017;20(2):191-+.
73. Flavahan WA, Drier Y, Liao BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. *Nature*. 2016;529(7584):110-+.
74. Zhao LT, Yang Y, Yin SG, Yang T, Luo J, Xie RK, et al. CTCF promotes epithelial ovarian cancer metastasis by broadly controlling the expression of metastasis-associated genes. *Oncotarget*. 2017;8(37):62217-30.
75. Li J, Huang KM, Hu GC, Babarinde IA, Li YY, Dong XT, et al. An alternative CTCF isoform antagonizes canonical CTCF occupancy and changes chromatin architecture to promote apoptosis. *Nature communications*. 2019;10.
76. Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, et al. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. *Cell Rep*. 2019;27(6):1781-93 e4.
77. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25(16):2078-9.
78. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Syst*. 2015;1(6):417-25.

RNA-seq for *CTCF*

a

b

c

d